J Korean Med Sci.  2020 Jun;35(25):e193. 10.3346/jkms.2020.35.e193.

Hip and Subtrochanteric or Femoral Shaft Fractures after Bisphosphonate Use in Korean Women, Using Korean National Sample Cohort

Affiliations
  • 1Department of Orthopedic Surgery, Seoul National University Bundang Hospital, Seongnam, Korea
  • 2Division of Statistics, Medical Research Collaborating Center, Seoul National University Bundang Hospital, Seongnam, Korea

Abstract

Background
Concern about bisphosphonate-associated subtrochanteric and femoral shaft (ST/FS) fractures has been raised. However, its real risk is still debatable, because there is no study to estimate risk and benefit of bisphosphonate. The objective of this study was to evaluate the risk of typical hip fractures and ST/FS fractures among bisphosphonate users using nationwide database.
Methods
We performed a retrospective cohort study using National Health Insurance Service-National Sample Cohort. We evaluated occurrence of the ST/FS and femoral neck and intertrochanteric (FN/IT) fractures among female bisphosphonate new users. Incidence rate of ST/FS and FN/IT fractures were compared between long-term users (≥ 1 year) and short-term users (< 1 year). Number needed to harm (NNH) for ST/FS and number needed to treat (NNT) for typical hip fracture were analyzed.
Results
Among 46,420 bisphosphonate users, we identified 14,689 long-term users and 21,840 short-term users. During the study period, 61 long-term users and 36 short-term users had ST/FS fractures, while 204 long-term users and 511 short-term users had FN/IT fractures. The long-term user showed higher incidence rate of ST/FS fractures (67.1/100,000 person-years; 95% confidence interval [CI], 50.3–83.9) comparing with 31.2/100,000 person-years (95% CI, 21.0–41.4) in the short-term users. The incidence rate of FN/IT fractures was 225.5/100,000 person-years (95% CI, 194.6–256.5) in the long-term users and 448.6/100,000 person-years (95% CI, 409.7–487.5) in the short-term users. The NNH for ST/FS was 400, while the NNT for typical hip fracture was 105.
Conclusion
Our study suggested that physicians keep the significant benefit of bisphosphonate to prevent typical hip fracture in mind, even the concerns about bisphosphonate-associated ST/FS fractures.

Keyword

Atypical Femur Fracture; Osteoporosis; Bisphosphonate; Hip Fracture; Fragility Fracture

Figure

  • Fig. 1 Flow chart of this study.ST = subtrochanteric, FS = femoral shaft, FN = femoral neck, IT = intertrochanteric.

  • Fig. 2 Cumulative incidence of subtrochanteric/femoral shaft fractures between bisphosphonate long-term users and short-term users.

  • Fig. 3 Cumulative incidence of femoral neck/intertrochanteric fractures between bisphosphonate long-term users and short-term users.


Reference

1. Altkorn D, Vokes T. Treatment of postmenopausal osteoporosis. JAMA. 2001; 285(11):1415–1418. PMID: 11255400.
Article
2. Levinson W, Altkorn D. Primary prevention of postmenopausal osteoporosis. JAMA. 1998; 280(21):1821–1822. PMID: 9846765.
Article
3. Cappola AR, Shoback DM. Osteoporosis therapy in postmenopausal women with high risk of fracture. JAMA. 2016; 316(7):715–716. PMID: 27533154.
Article
4. Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001; 286(22):2815–2822. PMID: 11735756.
Article
5. Pfister AK, Trotter CC. Bisphosphonate use and femoral fractures in older women. JAMA. 2011; 305(20):2068–2069.
Article
6. Sellmeyer DE. Atypical fractures as a potential complication of long-term bisphosphonate therapy. JAMA. 2010; 304(13):1480–1484. PMID: 20924014.
Article
7. Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA. 2011; 305(8):783–789. PMID: 21343577.
Article
8. Wang Z, Bhattacharyya T. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996–2007. J Bone Miner Res. 2011; 26(3):553–560. PMID: 20814954.
Article
9. Lee YK, Ha YC, Park C, Yoo JJ, Shin CS, Koo KH. Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry. Osteoporos Int. 2013; 24(2):707–711. PMID: 22618268.
Article
10. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014; 29(1):1–23. PMID: 23712442.
Article
11. Gustafsson A, Schilcher J, Grassi L, Aspenberg P, Isaksson H. Strains caused by daily loading might be responsible for delayed healing of an incomplete atypical femoral fracture. Bone. 2016; 88:125–130. PMID: 27113528.
Article
12. Teo BJ, Koh JS, Goh SK, Png MA, Chua DT, Howe TS. Post-operative outcomes of atypical femoral subtrochanteric fracture in patients on bisphosphonate therapy. Bone Joint J. 2014; 96-B(5):658–664. PMID: 24788502.
Article
13. Egol KA, Park JH, Rosenberg ZS, Peck V, Tejwani NC. Healing delayed but generally reliable after bisphosphonate-associated complete femur fractures treated with IM nails. Clin Orthop Relat Res. 2014; 472(9):2728–2734. PMID: 23604648.
Article
14. Prasarn ML, Ahn J, Helfet DL, Lane JM, Lorich DG. Bisphosphonate-associated femur fractures have high complication rates with operative fixation. Clin Orthop Relat Res. 2012; 470(8):2295–2301. PMID: 22669553.
Article
15. Schilcher J. High revision rate but good healing capacity of atypical femoral fractures. A comparison with common shaft fractures. Injury. 2015; 46(12):2468–2473. PMID: 26477344.
Article
16. Bogdan Y, Tornetta P 3rd, Einhorn TA, Guy P, Leveille L, Robinson J, et al. Healing time and complications in operatively treated atypical femur fractures associated with bisphosphonate use: a multicenter retrospective cohort. J Orthop Trauma. 2016; 30(4):177–181. PMID: 26709814.
17. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009; 24(6):1095–1102. PMID: 19113931.
Article
18. Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab. 2010; 95(12):5258–5265. PMID: 20843943.
Article
19. Vestergaard P, Schwartz F, Rejnmark L, Mosekilde L. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. Osteoporos Int. 2011; 22(3):993–1001. PMID: 21165600.
Article
20. Kim SY, Schneeweiss S, Katz JN, Levin R, Solomon DH. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res. 2011; 26(5):993–1001. PMID: 21542002.
Article
21. Wang Z, Ward MM, Chan L, Bhattacharyya T. Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries. Osteoporos Int. 2014; 25(8):2109–2116. PMID: 24846316.
Article
22. Hsiao FY, Huang WF, Chen YM, Wen YW, Kao YH, Chen LK, et al. Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women. Clin Ther. 2011; 33(11):1659–1667. PMID: 22018450.
Article
23. Ha YC, Kim TY, Lee A, Lee YK, Kim HY, Kim JH, et al. Current trends and future projections of hip fracture in South Korea using nationwide claims data. Osteoporos Int. 2016; 27(8):2603–2609. PMID: 27112763.
Article
24. Kim TY, Jang S, Park CM, Lee A, Lee YK, Kim HY, et al. Trends of incidence, mortality, and future projection of spinal fractures in Korea using Nationwide Claims Data. J Korean Med Sci. 2016; 31(5):801–805. PMID: 27134505.
Article
25. Choi HJ, Shin CS, Ha YC, Jang SM, Jang SH, Park CM, et al. Burden of osteoporosis in adults in Korea: a national health insurance database study. J Bone Miner Metab. 2012; 30(1):54–58. PMID: 21633927.
Article
26. Lee YK, Ha YC, Choi HJ, Jang S, Park C, Lim YT, et al. Bisphosphonate use and subsequent hip fracture in South Korea. Osteoporos Int. 2013; 24(11):2887–2892. PMID: 23681088.
Article
27. Ha YC, Lee YK, Lim YT, Jang SM, Shin CS. Physicians' attitudes to contemporary issues on osteoporosis management in Korea. J Bone Metab. 2014; 21(2):143–149. PMID: 25006571.
Article
28. Lee YK, Jang S, Ha YC. Management of osteoporosis in South Korea. Crit Rev Eukaryot Gene Expr. 2015; 25(1):33–40. PMID: 25955816.
Article
29. Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 2012; 27(12):2544–2550. PMID: 22836783.
Article
30. Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone. 2010; 47(2):169–180. PMID: 20493982.
31. Lo JC, Huang SY, Lee GA, Khandelwal S, Provus J, Ettinger B, et al. Clinical correlates of atypical femoral fracture. Bone. 2012; 51(1):181–184. PMID: 22414379.
Article
32. Marcano A, Taormina D, Egol KA, Peck V, Tejwani NC. Are race and sex associated with the occurrence of atypical femoral fractures? Clin Orthop Relat Res. 2014; 472(3):1020–1027. PMID: 24166075.
Article
33. Soh HH, Chua IT, Kwek EB. Atypical fractures of the femur: effect of anterolateral bowing of the femur on fracture location. Arch Orthop Trauma Surg. 2015; 135(11):1485–1490. PMID: 26286640.
Article
34. Chen LP, Chang TK, Huang TY, Kwok TG, Lu YC. The correlation between lateral bowing angle of the femur and the location of atypical femur fractures. Calcif Tissue Int. 2014; 95(3):240–247. PMID: 24980895.
Article
35. Lee YK, Ahn S, Kim KM, Suh CS, Koo KH. Incidence rate of atypical femoral fracture after bisphosphonates treatment in Korea. J Korean Med Sci. 2018; 33(5):e38. PMID: 29349947.
Article
36. Lee J, Lee JS, Park SH, Shin SA, Kim K. Cohort profile: the National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea. Int J Epidemiol. 2017; 46(2):e15. PMID: 26822938.
Article
37. Cheol Seong S, Kim YY, Khang YH, Heon Park J, Kang HJ, Lee H, et al. Data resource profile: the National Health Information Database of the National Health Insurance Service in South Korea. Int J Epidemiol. 2017; 46(3):799–800. PMID: 27794523.
Article
38. Korean National Health Insurance Service. Sample research DB. Updated 2015. Accessed May 31, 2017. http://nhiss.nhis.or.kr/bd/ab/bdaba022eng.do.
39. Kim L, Kim JA, Kim S. A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. Epidemiol Health. 2014; 36:e2014008. PMID: 25078381.
Article
40. Jung SY, Sohn HS, Park EJ, Suh HS, Park JW, Kwon JW. Oral bisphosphonates and upper gastrointestinal cancer risks in Asians with osteoporosis: a nested case-control study using national retrospective cohort sample data from Korea. PLoS One. 2016; 11(3):e0150531. PMID: 26937968.
Article
41. Schilcher J, Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop. 2009; 80(4):413–415. PMID: 19568963.
Article
42. Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011; 364(18):1728–1737. PMID: 21542743.
Article
43. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357(18):1799–1809. PMID: 17878149.
Article
44. Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016--executive summary. Endocr Pract. 2016; 22(9):1111–1118. PMID: 27643923.
Article
45. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013; 8(1-2):136. PMID: 24113837.
Article
46. Wang CC, Wu CH, Farley JF. Patterns of pharmacological treatment for osteoporosis among patients qualified for pharmacotherapy according to the national osteoporosis foundation guidelines. Ann Pharmacother. 2015; 49(9):995–1003. PMID: 26041809.
Article
47. Compston J. NOGG and NICE: new guidelines and quality standards for osteoporosis. Maturitas. 2017; 106:97–98. PMID: 28803757.
Article
48. Narongroeknawin P, Patkar NM, Shakoory B, Jain A, Curtis JR, Delzell E, et al. Validation of diagnostic codes for subtrochanteric, diaphyseal, and atypical femoral fractures using administrative claims data. J Clin Densitom. 2012; 15(1):92–102. PMID: 22071028.
Article
49. Park BJ, Sung JH, Park KD, Seo SW, Kim S. Report of the Evaluation for Validity of Discharged Diagnoses in Korean Health Insurance Database. Seoul: Seoul National University;2003.
50. Lee J, Lee JS, Park SH, Shin SA, Kim K. Cohort profile: the National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea. Int J Epidemiol. 2017; 46(2):e15. PMID: 26822938.
Article
Full Text Links
  • JKMS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr